Today: Today, Canaccord Genuity Reiterates “$140.00” Price Target for Edwards Lifesciences Corp (EW)

Today, Canaccord Genuity Reiterates “$140.00” Price Target for Edwards Lifesciences Corp (EW)

Canaccord Genuity set a $140.00 target price on Edwards Lifesciences Corp (NYSE:EW) in a report released on Tuesday. The firm currently has a buy rating on the medical research company’s stock.

A number of other brokerages have also recently weighed in on EW. Evercore ISI restated a hold rating and issued a $115.00 price objective on shares of Edwards Lifesciences Corp in a research note on Friday, August 19th. Credit Suisse Group AG set a $116.00 target price on shares of Edwards Lifesciences Corp and gave the company a buy rating in a research note on Thursday, August 18th. Morgan Stanley reiterated a buy rating and set a $140.00 target price on shares of Edwards Lifesciences Corp in a research note on Friday, August 19th. Leerink Swann reiterated a buy rating on shares of Edwards Lifesciences Corp in a research note on Friday, August 19th. Finally, Wells Fargo & Co. reiterated a buy rating on shares of Edwards Lifesciences Corp in a research note on Sunday, September 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-two have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $117.68.

Shares of Edwards Lifesciences Corp (NYSE:EW) opened at 86.86 on Tuesday. The company has a 50-day moving average of $102.00 and a 200 day moving average of $106.84. The company has a market capitalization of $18.57 billion, a P/E ratio of 34.33 and a beta of 0.71. Edwards Lifesciences Corp has a 12 month low of $72.20 and a 12 month high of $121.75.

Edwards Lifesciences Corp (NYSE:EW) last issued its quarterly earnings data on Tuesday, October 25th. The medical research company reported $0.68 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.68. Edwards Lifesciences Corp had a net margin of 19.24% and a return on equity of 24.32%. The business earned $739.40 million during the quarter, compared to analysts’ expectations of $749.14 million. During the same period in the previous year, the company earned $0.54 earnings per share. Edwards Lifesciences Corp’s revenue for the quarter was up 20.1% on a year-over-year basis. Analysts forecast that Edwards Lifesciences Corp will post $2.88 EPS for the current year.

In other Edwards Lifesciences Corp news, VP Donald E. Bobo, Jr. sold 18,000 shares of the firm’s stock in a transaction that occurred on Friday, September 2nd. The shares were sold at an average price of $115.78, for a total transaction of $2,084,040.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael A. Mussallem sold 49,100 shares of the firm’s stock in a transaction that occurred on Thursday, October 27th. The stock was sold at an average price of $92.77, for a total transaction of $4,555,007.00. The disclosure for this sale can be found here. 2.37% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Edwards Lifesciences Corp by 0.7% in the second quarter. Vanguard Group Inc. now owns 18,796,184 shares of the medical research company’s stock valued at $1,874,543,000 after buying an additional 134,432 shares during the period. FMR LLC increased its stake in shares of Edwards Lifesciences Corp by 1.2% in the second quarter. FMR LLC now owns 12,366,588 shares of the medical research company’s stock valued at $1,233,319,000 after buying an additional 141,713 shares during the period. BlackRock Institutional Trust Company N.A. increased its stake in shares of Edwards Lifesciences Corp by 1.5% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 5,542,619 shares of the medical research company’s stock valued at $668,218,000 after buying an additional 81,691 shares during the period. BlackRock Fund Advisors increased its stake in shares of Edwards Lifesciences Corp by 3.4% in the third quarter. BlackRock Fund Advisors now owns 4,337,584 shares of the medical research company’s stock valued at $522,939,000 after buying an additional 143,348 shares during the period. Finally, Ameriprise Financial Inc. increased its stake in shares of Edwards Lifesciences Corp by 1.6% in the third quarter. Ameriprise Financial Inc. now owns 4,320,603 shares of the medical research company’s stock valued at $520,896,000 after buying an additional 66,627 shares during the period. Hedge funds and other institutional investors own 83.99% of the company’s stock.

About Edwards Lifesciences Corp

Related posts

Leave a Comment